At BIO 2009 Symyx was promoting its new CDMO offering, which it believes meets a “real need in the industry” and can save clients time and materials by leveraging its prior knowledge.
Symyx launched its contract manufacture and development organisation (CDMO) after buying Integrity Bio and integrating the companies’ respective expertise.
Eric Carlson, vice president, life science technology, and Matthew Pino, director, business operations, explained Symyx’s CDMO offering to Outsourcing-Pharma.
The company believes it has expertise in preformulation development, formulation optimisation and stability and analytical method development. It also has the ability to perform fill/finish operations in compliance with current good manufacturing practices (cGMP).
Companies have given “very positive feedback” about the offering and have the option to work with Symyx to resolve a specific problem or in a broader developmental partnership.